{
    "nctId": "NCT03247738",
    "officialTitle": "Platelet Inhibition With CANgrelor and Crushed TICagrelor in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: The CANTIC Study",
    "inclusionCriteria": "* Patients with STEMI undergoing primary PPCI\n* Age \\> 18 years old\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Inability to provide written informed consent\n* Known history of prior intracranial bleeding\n* On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in the prior 10 days\n* Known allergies to aspirin, ticagrelor or cangrelor\n* On treatment with oral anticoagulant\n* Treatment with glycoprotein IIb/IIIa inhibitors\n* Fibrinolytics within 24 hours\n* Active bleeding\n* High risk of bleeding\n* Known platelet count \\<80x106/mL\n* Known hemoglobin \\<10 g/dL\n* Intubated patients (prior to randomization)\n* Known creatinine clearance \\<30 mL/minute or on hemodialysis.\n* Known severe hepatic dysfunction\n* Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection\n* Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.\n* Pregnant or lactating females."
}